The post Aptos – Is a potential bullish breakout ahead for APT’s price? appeared on BitcoinEthereumNews.com. Over the past week, the crypto market has seen someThe post Aptos – Is a potential bullish breakout ahead for APT’s price? appeared on BitcoinEthereumNews.com. Over the past week, the crypto market has seen some

Aptos – Is a potential bullish breakout ahead for APT’s price?

For feedback or concerns regarding this content, please contact us at [email protected]

Over the past week, the crypto market has seen some short-term success. Bitcoin [BTC] saw Spot ETF inflows and rising short-term demand. There was high volatility, but the liquidation figures were relatively tame. This was likely due to a fall in Open Interest after the strong downtrend since October.

In this environment of prevalent fear morphing into cautious optimism, Aptos [APT] has been challenging the $1 psychological round-number resistance. On Wednesday, 25 February, the altcoin rallied to a local high of $1.11. However, it soon retraced by 22% over the next three days.

Will APT bulls succeed in enforcing a bullish breakout this time?

Source: APT/USDT on TradingView

The long-term trend on the 1-day chart was bearish, but it was on the verge of beginning to reverse. The swing point at $1.008 was the most recent swing high of the downtrend. A breakout above this level would signal a shift in the long-term Aptos token price trends.

The A/D indicator has advanced strongly over the past two weeks, and the MFI was above 50. Together, they hinted at steady buying pressure and upward momentum.

Source: APT/USDT on TradingView

On the 4-hour chart, a triangle pattern emerged just below the $1 psychological resistance level. The A/D and MFI indicators were slightly bullish on this timeframe too. However, it was the rising triangle pattern that was most intriguing.

As buyers challenged the $1-level, they forced the price to form higher lows over the past week. This was a sign of conviction in a bullish breakout. Given the technical and psychological importance of the $1-level, the fact that the rejection from this resistance was overcome, and it was under siege so quickly, hinted at bullish strength.

Traders’ call to action – Cautiously bullish

Source: CoinGlass

The 1-month liquidation heatmap revealed a cluster of short liquidations from $1 to $1.12. Combined with the triangle pattern seen earlier, it might be highly likely that a bullish breakout would commence soon.

Traders can wait for the $1-level to be flipped to support before examining if it is a buying opportunity. With Bitcoin [BTC] also fighting to keep control of the psychological $70k, traders should remain cautious.


Final Summary

  • Aptos has a long-term bearish structure.
  • Formation of the rising triangle pattern in recent days under the $1-resistance meant a bullish breakout could be brewing.

Disclaimer: The information presented does not constitute financial, investment, trading, or other types of advice and is solely the writer’s opinion.

Next: DeFi Technologies gets Nasdaq warning after shares fall below $1

Source: https://ambcrypto.com/aptos-is-a-potential-bullish-breakout-ahead-for-apts-price/

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004868
$0.0004868$0.0004868
-6.65%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09